CINECA IRIS Institutional Research Information System

GRANCHI, CARLOTTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.308
EU - Europa 5.445
AS - Asia 5.121
SA - Sud America 877
AF - Africa 264
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 5
Totale 22.042
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.994
IT - Italia 2.768
SG - Singapore 1.608
CN - Cina 1.461
HK - Hong Kong 818
BR - Brasile 752
SE - Svezia 610
DE - Germania 459
BG - Bulgaria 317
VN - Vietnam 312
GB - Regno Unito 269
CA - Canada 228
FR - Francia 225
IN - India 211
TR - Turchia 189
RU - Federazione Russa 177
KR - Corea 153
AT - Austria 132
FI - Finlandia 130
JP - Giappone 73
UA - Ucraina 68
NL - Olanda 57
AR - Argentina 56
BE - Belgio 52
CI - Costa d'Avorio 47
MX - Messico 46
BD - Bangladesh 44
PL - Polonia 38
ZA - Sudafrica 37
ES - Italia 33
IQ - Iraq 31
NG - Nigeria 31
MA - Marocco 30
SN - Senegal 28
EG - Egitto 27
CH - Svizzera 23
PK - Pakistan 23
UZ - Uzbekistan 23
AU - Australia 20
IR - Iran 20
SA - Arabia Saudita 20
EC - Ecuador 19
ID - Indonesia 19
TW - Taiwan 16
VE - Venezuela 16
CZ - Repubblica Ceca 15
CO - Colombia 14
TN - Tunisia 13
IE - Irlanda 12
IL - Israele 12
DZ - Algeria 10
KE - Kenya 9
AZ - Azerbaigian 8
GH - Ghana 8
JO - Giordania 8
LT - Lituania 8
RO - Romania 8
AE - Emirati Arabi Uniti 7
DK - Danimarca 7
TT - Trinidad e Tobago 7
CL - Cile 6
DO - Repubblica Dominicana 6
MY - Malesia 6
OM - Oman 6
PA - Panama 6
PT - Portogallo 6
QA - Qatar 6
HN - Honduras 5
HU - Ungheria 5
KW - Kuwait 5
NP - Nepal 5
TH - Thailandia 5
AM - Armenia 4
AO - Angola 4
BY - Bielorussia 4
ET - Etiopia 4
GR - Grecia 4
JM - Giamaica 4
PY - Paraguay 4
SK - Slovacchia (Repubblica Slovacca) 4
UY - Uruguay 4
AL - Albania 3
BJ - Benin 3
GE - Georgia 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LB - Libano 3
LY - Libia 3
MO - Macao, regione amministrativa speciale della Cina 3
PE - Perù 3
RS - Serbia 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BO - Bolivia 2
CR - Costa Rica 2
CU - Cuba 2
EU - Europa 2
GA - Gabon 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
Totale 22.007
Salva come PNG Salva come JPEG
Città #
Ashburn 1.045
Serra 970
Woodbridge 961
Singapore 886
Fairfield 839
Hong Kong 811
Dallas 768
Ann Arbor 626
Houston 600
Chandler 581
Santa Clara 510
Seattle 357
Shanghai 329
Sofia 317
Beijing 309
Wilmington 294
Cambridge 292
New York 236
Milan 222
Hefei 199
Los Angeles 191
Boardman 182
Princeton 162
Ottawa 154
Pisa 142
Seoul 122
Florence 116
Lawrence 114
Vienna 114
Medford 107
Munich 101
Izmir 99
Marseille 89
London 88
Rome 87
Nanjing 84
Des Moines 81
Dearborn 76
Redondo Beach 69
Jacksonville 67
Boulder 66
Redwood City 64
Istanbul 60
Dong Ket 59
São Paulo 58
Council Bluffs 56
Ho Chi Minh City 55
Lucca 54
Livorno 49
Tokyo 49
Abidjan 46
Buffalo 41
Hyderabad 40
Frankfurt am Main 39
Ogden 39
San Diego 38
Hanoi 35
Turku 35
Chicago 33
The Dalles 33
Lagos 31
Nanchang 31
Belo Horizonte 28
Dakar 28
Bologna 27
Brussels 27
Mumbai 27
Rio de Janeiro 27
San Francisco 27
San Jose 26
Columbus 25
Kunming 23
Warsaw 22
Düsseldorf 21
Nuremberg 20
Vicopisano 20
Washington 20
Hangzhou 19
Casablanca 17
Chennai 17
Denver 17
Helsinki 17
Louvain-la-Neuve 17
Mexico City 17
Pessac 17
Shenyang 17
Tashkent 17
Turin 17
Ankara 16
Atlanta 16
Guangzhou 16
Hebei 16
Montreal 16
Pistoia 16
Toronto 16
Johannesburg 15
Manchester 15
Phoenix 15
Amsterdam 14
Auburn Hills 14
Totale 15.150
Salva come PNG Salva come JPEG
Nome #
COMPOSTO INIBITORE DELL’ENZIMA LATTATO DEIDROGENASI (LDH) E COMPOSIZIONE FARMACEUTICA CHE COMPRENDE TALE COMPOSTO 346
4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors 315
Glycoconjugated metal complexes as cancer diagnostic and therapeutic agents 282
Receptor-based virtual screening evaluation for the identification of estrogen receptor β ligands 252
Phenylpropanoids and flavonoids from Phlomis kurdica as inhibitors of human lactate dehydrogenase. 252
GLUT1 and LOX inhibitors as perspective anticancer agents tackling glucose avidity and ECM remodeling in tumors 246
Synthesis and biological evaluation of non-glucose glycoconjugated N-hydroyxindole class LDH inhibitors as anticancer agents 227
New activators of SIRT1 enzyme for the treatment of cardiovascular and cardiometabolic pathologies 226
Identification of Lactate Dehydrogenase 5 Inhibitors using Pharmacophore- Driven Consensus Docking 225
Sonde diagnostiche per evidenziare all’infrarosso cellule e tessuti affetti da condizioni patologiche o metaboliche 213
Nuovi attivatori dell’enzima SIRT1 per il trattamento delle patologie cardiovascolari e cardiometaboliche 205
Synthesis and Biological Evaluation of New Glycoconjugated LDH Inhibitors as Anticancer Agents 205
A Virtual Screening Study for Lactate Dehydrogenase 5 Inhibitors by using a Pharmacophore-Based Approach 204
Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors 204
First examples of H2S-releasing glycoconjugates: stereoselective synthesis and anticancer activities 201
Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death 195
Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials 193
Salicylaldoxime derivatives as new leads for the development of carbonic anhydrase inhibitors 192
Rational Development of MAGL Inhibitors 192
Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor 190
Discovery of N-Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform a (LDH-A) as Starvation Agents against Cancer Cells 187
Glucose transporters: production, crystallization and inhibition 187
Structural optimization of 4-chlorobenzoylpiperidine derivatives for the development of potent, reversible and selective monoacylglycerol lipase (MAGL) inhibitors 184
COMPOUNDS INHIBITING THE ENZYME LACTATE DEHYDROGENASE (LDH), PHARMACEUTICAL COMPOSITIONS AND USES THEREOF 183
Characterization of the Saffron Derivative Crocetin as an Inhibitor of Human Lactate Dehydrogenase 5 in the Antiglycolytic Approach against Cancer 183
Historical perspective of tumor glycolysis: a century with Otto Warburg 182
Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer 182
Antiproliferative oxime derivatives that inhibit glucose transporter 1 (GLUT1) in cancer cells 181
Identification of new FYN kinase inhibitors using a FLAP-based approach 181
Diagnostic probes to detect cells and tissues afflicted with a pathological or metabolic condition by means of infrared spectroscopy 181
Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors 179
Hypoxia-activated lysyl oxidase (LOX) inhibitors in the treatment of highly invasive and metastatic cancer 178
Estrogen receptor ligands: a patent review update 178
Design, Synthesis, and Evaluation of GLUT Inhibitors 178
Reactive Oxygen Species Synergize to Potently and Selectively Induce Cancer Cell Death 177
Anticancer Agents That Counteract Tumor Glycolysis 176
Phenylethanoid glycosides from Cistanche phelypaea acting as monoacylglycerol lipase inhibitors 176
Dual Targeting of the Warburg Effect with a Glucose-Conjugated Lactate Dehydrogenase Inhibitor 174
Highly Selective Salicylketoxime-Based Estrogen Receptor β Agonists Display Antiproliferative Activities in a Glioma Model 174
An update on therapeutic opportunities offered by cancer glycolytic metabolism 173
Cyclic Ketoximes as Estrogen Receptorβ Selective Agonists 173
Risks and Benefits Related to Alimentary Exposure to Xenoestrogens 173
Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia 171
Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes 170
Discovery of 1,5-Diphenylpyrazole-3-Carboxamide Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors 170
Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways 170
Computationally driven discovery of phenyl(piperazin-1-yl)methanone derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors 170
Design, synthesis, ADME and biological evaluation of benzylpiperidine and benzylpiperazine derivatives as novel reversible monoacylglycerol lipase (MAGL) inhibitors 168
Anticancer agents interacting with membrane glucose transporters 168
Functionalized aliphatic polyketones with germicide activity 166
Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds 165
Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5 164
Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells 164
Biphenyl-Derivatives Possessing Tertiary Amino Groups as ß-Secretase (BACE1) Inhibitors 163
Preclinical emergence of novel lactate dehydrogenase inhibitors as potent antitumor agents in hypoxic models of pancreatic cancer: molecular mechanisms underlying their synergistic interaction with gemcitabine 162
N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation 162
Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. 159
Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors 158
Clerodanes from Salvia pseudorosmarinus and their activity as inhibitors of monoacylglycerol lipase (MAGL) 158
Triazole-substituted N-hydroxyindol-2-carboxylates as inhibitors of isoform 5 of human lactate dehydrogenase (hLDH5) 157
Bioactive heterocycles containing endocyclic N-hydroxy groups 157
N-Hydoxyindoles: novel, selective, and efficient inhibitors of isoform 5 of human lactate dehydrogenase (hLDH-5) 156
Natural compounds as inhibitors of lactate dehydrogenase 155
ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism 155
An Update on Patents Covering Agents That Interfere with the Cancer Glycolytic Cascade 155
Salicylketoximes that target glucose transporter 1 restrict energy supply to lung cancer cells 155
Small-molecule inhibitors of human LDH5 153
Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high-grade serous ovarian cancer 152
Reversible Monoacylglycerol Lipase Inhibitors: Discovery of a New Class of Benzylpiperidine Derivatives 150
BACE1 inhibitory activities of enantiomerically pure, variously substituted N-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropyl) arylsulfonamides 149
Bioreductively Activated Lysyl Oxidase Inhibitors against Hypoxic Tumours 149
Application of MM-PBSA methods in virtual screening 149
Abstract 3082: Targeting hypoxic pancreatic cancer cells with glucose conjugated lactate dehydrogenase inhibitor NHI-Glc-2 147
Effect of Tumor Relevant Acidic Environment in the Interaction of a N-hydroxyindole-2-Carboxylic Derivative with the Phospholipid Bilayer 146
Nuovi inibitori reversibili della monoacilglicerolo lipasi (MAGL) quali potenziali agenti antitumorali, antiinfiammatori e neuroprotettivi. 146
Constituents of Polygala flavescens ssp. flavescens and their activity as inhibitors of human lactate dehydrogenase 145
A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017) 145
Activators of Sirtuin-1 and their Involvement in Cardioprotection 145
AGENTI TERAPEUTICI IN GRADO DI RIDURRE LA PRODUZIONE CELLULARE DI ACIDO LATTICO E COMPOSIZIONI FARMACEUTICHE CHE COMPRENDONO TALI COMPOSTI 144
The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies 144
Carbazole-containing arylcarboxamides as BACE1 inhibitors 143
First-of-its-kind STARD 3 Inhibitor: In Silico Identification and Biological Evaluation as Anticancer Agent 142
Development and validation of a docking-based virtual screening platform for the identification of new lactate dehydrogenase inhibitors 141
An updated patent review of monoacylglycerol lipase (MAGL) inhibitors (2018-present) 141
Nuovi agenti antivirali a struttura N-idrossiindrol-carbossamidica 140
Salicylketoximes as inhibitors of Glucose Transporters 139
VenomPred 2.0: A Novel In Silico Platform for an Extended and Human Interpretable Toxicological Profiling of Small Molecules 137
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies 137
New phenylethanoid glycosides from Cistanche phelypaea and their activity as inhibitors of monoacylglycerol lipase (MAGL) 136
Inhibitors of lactate dehydrogenase (hLDH5) from Polygala flavescens subsp. flavescens 133
Machine Learning-Based Virtual Screening for the Identification of Cdk5 Inhibitors 132
Hypoxia-activated lysyl oxidase (LOX) inhibitors in the treatment of highly invasive and metastatic cancer 132
Synergistic Interaction of Novel Lactate Dehydrogenase Inhibitors with Gemcitabine in Hypoxic Models of Pancreatic Cancer 132
Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds 131
alpha-Naphthylaminopropan-2-ol Derivatives as BACE1 Inhibitors 130
Aminobenzothiazoles as inhibitors of tau-fibril formation in Alzheimer's and other neurodegenerative diseases 130
Identification and characterization of a new reversible MAGL inhibitor 130
First-in-Class Dual Targeting Compounds for the Management of Seizures in Glucose Transporter Type 1 Deficiency Syndrome 129
New diterpenes from Salvia pseudorosmarinus and their activity as inhibitors of monoacylglycerol lipase (MAGL) 129
Estrogen Receptors Alpha (ERα) and Beta (ERβ): Subtype-Selective Ligands and Clinical Potential 127
Totale 17.158
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.759
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.759
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021791 0 0 0 0 0 0 63 132 189 95 102 210
2021/20221.769 88 114 57 103 229 274 72 100 62 76 94 500
2022/20232.120 231 291 169 173 234 281 33 155 355 19 144 35
2023/20241.536 129 122 127 96 203 251 113 67 31 54 116 227
2024/20255.199 69 182 147 281 419 502 400 264 496 605 624 1.210
2025/20263.937 373 818 919 688 605 526 8 0 0 0 0 0
Totale 22.496